Imugene hits 82% response rate in blood cancer trial - ICYMI

Core Insights - Imugene Ltd reported new clinical data from its Phase 1b trial evaluating azer-cel in patients with diffuse large B-cell lymphoma (DLBCL), including those who previously failed CAR-T therapies [1] Group 1: Clinical Trial Results - The trial achieved an 82% overall response rate in the CAR-T-fail population, with every patient experiencing either a complete response (CR) or partial response (PR) [2][10] - In a second cohort of CAR-T-naive patients, the response rate was reported at 83%, with enrollment in this group more than tripling since it opened [4][12] - Some patients initially recorded as partial responders have converted to complete responders, aligning with the typical response time for CAR-T treatments [3][11] Group 2: Patient Outcomes - The first patient dosed in 2024 has maintained a complete response for over 19 months, with many participants having undergone two to six previous lines of therapy [5][13] - Some patients have become eligible for allogeneic stem cell transplants, which could be curative in certain cases [5][13] Group 3: Regulatory and Future Plans - The company held a positive meeting with the FDA and expects to receive official meeting minutes within approximately 30 days [6][14] - Imugene plans to continue enrollment and monitoring in both patient cohorts and will provide further updates as data matures [6]